• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

BioIntelliSense and Medically Home Partner to Enhance High Acuity Hospital Care at Home

Share:

November 14, 2022

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced it has entered into a strategic partnership with Medically Home Group, Inc., a technology-enabled services company that is at the forefront of the movement to decentralize care for serious or complex illnesses.

– The collaboration further expands the availability of continuous biometric data and insights to physicians and nurses caring for patients in the Medically Home model with serious, complex or high-risk illness being cared for in their homes while accelerating the adoption of medical grade BioButton® wearable devices.

BioButton Background

The rechargeable multi-parameter BioButton® wearable devices passively capture clinically validated vital signs of heart rate at rest, respiratory rate at rest and skin temperature, along with a broad range of physiologic biometrics, including activity levels, sleep tracking, body position and gait analysis. The BioCloud™ data analytics and algorithmic-based alerting enable actionable clinical triage and proactive clinical intervention through potential earlier detection of adverse trends.

The Medically Home model directly addresses the growing need for increased health system capacity and resiliency, while meeting the needs and preferences of patients, who often desire to be cared for in the comfort and convenience of their home. With the comprehensive Medically Home and BioIntelliSense solution, patients with conditions across a broad spectrum of severity, complexity, and risk can continue to be cared for safely at home with clinical accuracy, reducing the necessity for traditional building-centric care.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“BioIntelliSense provides a scalable medical-grade solution that allows for passive vital sign data collection from the home, dramatically reducing the cost and complexity of deploying traditional remote patient monitoring programs with improved patient experience,” said Pippa Shulman, DO, MPH, Chief Medical Officer, Medically Home. “As hospital capacity pressure mounts, this strategic collaboration further accelerates Medically Home’s platform reach and growing ecosystem of health systems and payers nationwide.”

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • InnoCare and ArriVent Announce Clinical Development CollaboratioInnoCare and ArriVent Announce Clinical Development Collaboratio
  • The Lack Of Medical Device Security — Accidents Waiting To HappenThe Lack Of Medical Device Security — Accidents Waiting To Happen
  • athenahealth Launches Its First Embedded Telehealth Solution at No Additional Costathenahealth Launches Its First Embedded Telehealth Solution at No Additional Cost
  • Atrium Health, Best Buy Ink Hospital-At-Home DealAtrium Health, Best Buy Ink Hospital-At-Home Deal
  • 4 disruptions AI could cause in healthcare4 disruptions AI could cause in healthcare
  • CSA Service Solutions, LLC Acquires Equipment Management Service and Repair, Inc.CSA Service Solutions, LLC Acquires Equipment Management Service and Repair, Inc.
  • Merck Leans Into Immunology with $10.8B Prometheus BuyMerck Leans Into Immunology with $10.8B Prometheus Buy
  • LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NI, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NI, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications